user

Phase II trial of idarubicin, fludarabine, Ara-C, and filgrastim filgrastim (G-CSF) (Ida-FLAG) for treatment of poor prognosis acute myeloid leukemia (AML).

被引：0
|
作者：
Wickramanayake, PD [1 ]
Steinmetz, HT [1 ]
Katay, I [1 ]
Glasmacher, A [1 ]
Staib, P [1 ]
Diehl, V [1 ]
机构：
[1] UNIV HOSP KOLN,DEPT INTERNAL MED 1,COLOGNE,GERMANY
来源：
BLOOD | 1995年 / 86卷 / 10期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：3009 / 3009
页数：1
相关论文
共 50 条
  • [21] Fludarablne, ARA-C, G-CSF with or without mitoxantrone (FLANG-FLAG) are tolerable and effective in bad prognosis acute myeloid leukemia patients
    Gobbi, M
    Clavio, M
    Miglino, M
    Carrara, P
    Gatti, AM
    Balleari, E
    Cerri, R
    Bruni, R
    Pierri, I
    Canepa, L
    Celesti, L
    Vallebella, E
    Cavaliere, M
    Pietrasanta, D
    Ghio, R
    Damasio, E
    BRITISH JOURNAL OF HAEMATOLOGY, 1996, 93 : 829 - 829
  • [22] FLAG-IDA regimen (fludarabine, cytarabine, idarubicin and G-CSF) in the treatment of patients with high-risk myeloid malignancies
    de la Rubia, J
    Regadera, AI
    Martín, G
    Cervera, J
    Sanz, G
    Martínez, JA
    Jarque, I
    García, I
    Andreu, R
    Moscardó, F
    Jiménez, C
    Mollá, S
    Benlloch, L
    Sanz, MA
    LEUKEMIA RESEARCH, 2002, 26 (08) : 725 - 730
  • [23] Treatment of "poor risk" acute myeloid leukemia with fludarabine, cytarabine and G-CSF (FLAG regimen): A single center study
    Carella, AM
    Cascavilla, N
    Greco, MM
    Melillo, L
    Sajeva, MR
    Ladogana, S
    D'Arena, G
    Perla, G
    Carotenuto, M
    LEUKEMIA & LYMPHOMA, 2001, 40 (3-4) : 295 - 303
  • [24] Multicentre phase III trial on fludarabine, cytarabine (Ara-C), and idarubicin versus idarubicin, Ara-C and etoposide for induction treatment of younger, newly diagnosed acute myeloid leukaemia patients
    Russo, D
    Malagola, M
    Vivo, A
    Fiacchini, M
    Martinelli, G
    Piccaluga, PP
    Damiani, D
    Candoni, A
    Michielutti, A
    Castelli, M
    Testoni, N
    Ottaviani, E
    Rondoni, M
    Pricolo, G
    Mazza, P
    Zuffa, E
    Zaccaria, A
    Raspadori, D
    Bocchia, M
    Lauria, F
    Bonini, A
    Avanzini, P
    Gugliotta, L
    Visani, G
    Fanin, R
    Baccarani, M
    BRITISH JOURNAL OF HAEMATOLOGY, 2005, 131 (02) : 172 - 179
  • [25] Treatment of chronic myeloid leukemia in the blastic phase with fludarabine, cytosine arabinoside and G-CSF (FLAG)
    Tedeschi, A
    Montillo, M
    Ferrara, F
    Nosari, A
    Mele, G
    Copia, C
    Leoni, P
    Morra, E
    EUROPEAN JOURNAL OF HAEMATOLOGY, 2000, 64 (03) : 182 - 187
  • [26] A combination of idarubicin, fludarabine, Ara-C and G-CSF (IFLAG) induction followed by high dose busulfan/cytoxan and peripheral blood stem cell rescue in patients with myelodysplastic syndrome in transformation and poor prognosis acute myelogenous leukemia (AML).
    Besa, EC
    Trottman, J
    Klease, C
    Brehm, P
    Rovito, M
    BLOOD, 1995, 86 (10) : 3148 - 3148
  • [27] FLAG-IM (fludarabine, Ara-C, G-CSF, idarubicin, mylotarg) is an effective salvage regimen producing high rates of remission (CR plus CRi) in relapsed/refractory AML
    Goyal, Sagun D.
    Uy, Geoffrey L.
    Augustin, Kristan M.
    Hladnik, Lindsay
    Abboud, Camille N.
    Cashen, Amanda F.
    Westervelt, Peter
    DiPersio, John F.
    Vij, Ravi
    BLOOD, 2007, 110 (11) : 549A - 549A
  • [28] Fludarabine, Cytarabine and G-CSF (FLAG) as treatment of de novo acute myeloid leukemia with multilineage dysplasia.
    Ferrara, F
    Palmieri, S
    Schiavone, EM
    Annunziata, M
    Copia, C
    Annunziata, S
    Gianfaldoni, G
    Leoni, F
    BLOOD, 2001, 98 (11) : 212B - 212B
  • [29] Fludarabine, cytarabine and G-CSF (FLAG) for the treatment of acute myeloid leukemia (AML) relapsing from autologous bone marrow transplantation (A-BMT).
    Ferrara, F
    Melillo, L
    Montillo, M
    Leoni, F
    Pinto, A
    Mele, G
    Mirto, S
    BLOOD, 1998, 92 (10) : 656A - 656A
  • [30] Phase I/II study of idarubicin (Ida), high-dose ara-C, and sorafenib (S) in patients (pts) younger than 65 years with acute myeloid leukemia (AML)
    Kashani, F. Ravandi
    Cortes, J.
    Faderl, S.
    Jones, D.
    Byrd, A.
    Brandt, M.
    Garcia-Manero, G.
    Levis, M.
    Andreeff, M.
    Kantarjian, H.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
12345